Embecta Corp.

NasdaqGS:EMBC Lagerbericht

Marktkapitalisierung: US$546.6m

Embecta Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Für Embecta wird ein Gewinn- und Umsatzwachstum von 5.7% bzw. 0.1% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 3.7% pro Jahr steigen soll.

Wichtige Informationen

5.7%

Wachstumsrate der Gewinne

3.73%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum16.0%
Wachstumsrate der Einnahmen0.1%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Low

Zuletzt aktualisiert30 Apr 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 09
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

US$16.67: That's What Analysts Think Embecta Corp. (NASDAQ:EMBC) Is Worth After Its Latest Results

Nov 28
US$16.67: That's What Analysts Think Embecta Corp. (NASDAQ:EMBC) Is Worth After Its Latest Results

Recent updates

EMBC: Wound Care Expansion Will Support Future Upside Despite Lower Price Targets

Analysts have trimmed their targets on Embecta by $2 to $3, citing updated expectations that align with an unchanged fair value estimate of $15, a steady discount rate of 12.33%, and consistent long term assumptions for revenue trends, profit margin, and a future P/E of about 7.9x. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed fair value estimate of $15 and implied P/E of about 7.9x as leaving room for the share price to close part of the gap if execution on the existing plan remains consistent.

EMBC: Higher Discount Rate And Wound Care Expansion Will Support Future Upside

Analysts have adjusted Embecta's implied fair value price target from $16.67 to $15.00, reflecting updated views on discount rates, revenue trends, profit margins and future P/E assumptions following recent research, including price target cuts from both Mizuho and BTIG. Analyst Commentary Recent research updates point to a more cautious stance on Embecta, with the lower implied fair value aligning with trimmed price targets and more conservative assumptions around growth, profitability and P/E levels.

Embecta: An Interesting Deal At An Interesting Time

Mar 19

EMBC: Future M&A And Margin Pressures Will Shape Balanced Outlook

Analysts have maintained Embecta's price target at $11.00, citing updated assumptions that include a slightly lower discount rate, softer revenue growth expectations, a reduced profit margin outlook, and a higher future P/E multiple. What's in the News Embecta is actively exploring mergers and acquisitions, with leadership emphasizing a focus on chronic care drug delivery where the company can use its manufacturing strengths and growing B2B channel (Key Developments).

Embecta's (NASDAQ:EMBC) Solid Earnings Have Been Accounted For Conservatively

Feb 12
Embecta's (NASDAQ:EMBC) Solid Earnings Have Been Accounted For Conservatively

Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 09
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15

Feb 08
Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15

EMBC: Future M&A Plans Will Test Balance Sheet And Earnings Multiple

Analysts now hold their fair value estimate for Embecta at US$11.00. The unchanged target reflects modest tweaks to assumptions around revenue growth, profit margin and future P/E that offset the slightly higher discount rate.

EMBC: Future M&A Ambitions Will Heighten Risk Against Weak Earnings Multiple

Analysts have kept their fair value estimate for Embecta steady at US$11.00 while slightly adjusting underlying assumptions around discount rate, revenue growth, profit margins, and forward P/E. This reflects updated views on the company’s risk profile and earnings power without a change to the headline target.

Market Cool On Embecta Corp.'s (NASDAQ:EMBC) Earnings

Jan 09
Market Cool On Embecta Corp.'s (NASDAQ:EMBC) Earnings

EMBC: Medium Term Guidance Will Balance Revenue Outlook With Margin Pressures

Analysts have modestly trimmed their price target on Embecta to 11.00 dollars, reflecting slightly higher discount rate assumptions and a marginally lower anticipated future P or E multiple, partially offset by incrementally stronger expectations for revenue growth and profit margins. What's in the News Embecta issued new fiscal 2026 guidance, projecting reported revenues between 1,071 million and 1,093 million dollars, signaling confidence in its medium term growth trajectory (Key Developments).

EMBC: Outlook Will Balance Stabilizing Revenues With Pressured Profit Margins Through 2026

Analysts have modestly raised their price target on Embecta to 11.00 dollars from 11.00 dollars. This reflects improved expectations for a return to positive revenue growth and a higher future earnings multiple, partially offset by a higher discount rate and slightly lower projected profit margins.

US$16.67: That's What Analysts Think Embecta Corp. (NASDAQ:EMBC) Is Worth After Its Latest Results

Nov 28
US$16.67: That's What Analysts Think Embecta Corp. (NASDAQ:EMBC) Is Worth After Its Latest Results

Is Now The Time To Look At Buying Embecta Corp. (NASDAQ:EMBC)?

Nov 01
Is Now The Time To Look At Buying Embecta Corp. (NASDAQ:EMBC)?

Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price

Sep 26
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price

Even With A 29% Surge, Cautious Investors Are Not Rewarding Embecta Corp.'s (NASDAQ:EMBC) Performance Completely

Aug 28
Even With A 29% Surge, Cautious Investors Are Not Rewarding Embecta Corp.'s (NASDAQ:EMBC) Performance Completely

GLP-1 Partnerships Will Expand Global Healthcare Reach

The consensus price target for Embecta has been cut from $18.33 to $16.00, primarily reflecting lowered revenue growth forecasts and a declining future P/E multiple. What's in the News Embecta Corp.

Sentiment Still Eluding Embecta Corp. (NASDAQ:EMBC)

Jul 04
Sentiment Still Eluding Embecta Corp. (NASDAQ:EMBC)

Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15

May 22
Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15

What Is Embecta Corp.'s (NASDAQ:EMBC) Share Price Doing?

May 09
What Is Embecta Corp.'s (NASDAQ:EMBC) Share Price Doing?

Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price

Mar 06
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price

Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour

Feb 28

New Initiatives Expected To Make Embecta More Profitable

Dec 04

Embecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15

Nov 29
Embecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15

At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?

Nov 07
At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?

It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)

Sep 24
It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)
User avatar

Expanding Global Leadership In Insulin Devices Fuels Revenue Growth And Operational Efficiencies

Strengthening the base business in insulin injection devices suggests potential for stable, growing revenues as the global demographic needing these devices increases.

Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15

Aug 16
Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15

Embecta Corp. Just Beat EPS By 79%: Here's What Analysts Think Will Happen Next

Aug 14
Embecta Corp. Just Beat EPS By 79%: Here's What Analysts Think Will Happen Next

When Should You Buy Embecta Corp. (NASDAQ:EMBC)?

Jul 13
When Should You Buy Embecta Corp. (NASDAQ:EMBC)?

Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

May 12
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Embecta's (NASDAQ:EMBC) Dividend Will Be $0.15

Feb 21
Embecta's (NASDAQ:EMBC) Dividend Will Be $0.15

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:EMBC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
9/30/20281,078165152N/A3
9/30/20271,071152154N/A4
9/30/20261,071149140N/A4
12/31/20251,080140206214N/A
9/30/20251,08095182192N/A
6/30/20251,10384132134N/A
3/31/20251,080534051N/A
12/31/20241,108582944N/A
9/30/20241,123782036N/A
6/30/20241,119701439N/A
3/31/20241,13370932N/A
12/31/20231,12255-30-6N/A
9/30/20231,121704168N/A
6/30/20231,114477096N/A
3/31/20231,11994114138N/A
12/31/20221,116160309334N/A
9/30/20221,130224388412N/A
6/30/20221,156338411440N/A
3/31/20221,160380506537N/A
12/31/20211,169408442474N/A
9/30/20211,165415417456N/A
9/30/20201,086428457499N/A
9/30/20191,109432N/A505N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: EMBCDas prognostizierte Gewinnwachstum (5.7% pro Jahr) liegt über der Sparquote (3.4%).

Ertrag vs. Markt: EMBCDie Erträge des Unternehmens (5.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (16% pro Jahr).

Hohe Wachstumserträge: EMBCDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: EMBCDie Einnahmen des Unternehmens (0.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.1% pro Jahr).

Hohe Wachstumseinnahmen: EMBCDie Einnahmen des Unternehmens (0.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von EMBC in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/03 11:07
Aktienkurs zum Tagesende2026/05/01 00:00
Gewinne2025/12/31
Jährliche Einnahmen2025/09/30

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Embecta Corp. wird von 7 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Travis SteedBofA Global Research
Travis SteedBofA Global Research
Michael GormanBTIG